Cite
HARVARD Citation
Kelley, R. et al. (n.d.). 702POutcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC). Annals of oncology. p. . [Online].